Molecular profile and cell cycle in mcf-7 cells resistant to cisplatin and doxorubicin by Lukyanova, N.Yu. et al.
Experimental Oncology 31, 87–91, 2009 (June) 87
Tumor drug resistance is one of the most impor-
tant problems in cancer treatment in general as well 
as breast cancer treatment [1–3]. Many chemothera-
peutic schedules used in breast cancer treatment 
include anthracyclines and platinum derivatives [2, 
3]. Cisplatin belongs to the group of alkylating agents. 
It binds to DNA bases causing crosslinks and breaks 
in DNA strands interfering with DNA replication [4]. 
The antitumor effects of doxorubicin are associated 
with DNA intercalation and degradation of the tubu-
lar apparatus caused by the active free radicals [5]. 
The mechanisms of drug resistance development 
for these two drugs are different [4–7]. It is believed 
that cisplatin resistance is caused by an expression 
of proteins involved in glutathione-mediating detoxify-
ing pathways such as glutathione-S-transferase, glu-
tathione-reductase and glutathione itself [8, 9]. DOX 
resistance, as believed, results from the overexpres-
sion of 170 kD Pgp glycopeptide, which is an energy-
dependent pump that effluxes xenobiotics away from 
cells [10, 11]. It is also known that the development 
of drug resistance phenotype could be accompanied 
by changes in morphological structure, proliferative 
potential and adhesion properties of cells as well as the 
changes in expression of proteins involved in apoptosis 
and cell cycle control [12–15]. Studies on mecha-
nisms of antitumor drug resistance development are 
of paramount importance for further understanding 
of fundamental processes in formation of drug resis-
tance phenotype in tumors with the aim of searching 
the ways for overcoming such resistance. 
The aim of the study was to compare the ultrastruc-
ture, phenotypic profile and cell cycle of MCF-7 human 
breast cancer cells and sublines resistant to cytotoxic 
effects of cisplatin (MCF-7/DDP) and doxorubicin 
(MCF-7/DOX).
MATERIALS AND METHODS
Cell lines and drug treatment. For our studies 
we used human breast cancer cell line MCF-7 and 
its sublines resistant to cytotoxic effects of cisplatin 
(MCF-7/DDP) and doxorubicin (MCF-7/DOX). The 
cells of the initial MCF-7 line were cultivated in modi-
fied Dulbecco’s medium ISCOV (“Sigma”, Germany) 
with addition of 10% of fetal calf serum (“Sangva”, 
Ukraine) at the temperature of 37 °C and CO2 concen-
tration of 5%. Cells were reseeded twice a week at the 
density 2–4 x 104 cells/cm2, when cell layer covered 
about half of the flask surface.
The resistant variants MCF-7/DOX and MCF-7/DDP 
were originated by growing initial MCF-7 cells with rai-
sing concentrations of cisplatin (from 0.01 to 6 µg/ml) 
or doxorubicin (from 0.1 to 32 µg/ml), respectively. 
Cisplatin and doxorubicin were added twice a week 
after reseeding. Every two months, cell survival was 
analyzed by MTT assay. IC50 values for MCF-7 and 
MCF-7/DDP cells were 0.25 and 1 µg/ml of cisplatin, 
respectively, and for MCF-7 and MCF-7/DOX cells — 
0.5 and 8 µg/ml of doxorubicin, respectively. There-
fore, MCF-7/DDP were 4 times as much resistant 
to the cytotoxic effect of cisplatin and MCF-7/DOX 
cells were 16 times as much resistant to the cyto-
toxic effect doxorubicin as compared with the initial 
MCF-7 cells. 
MTT assay. Sensitivity to antitumor drugs (cis-
platin and doxorubicin) was measured every two 
months using standard MTT-colorimetric test with 
3-[4,5,dimethylthiasol-2-1]-2,5-diphenyltetrasolium 
bromide (“Sigma”, Germany) [16].
Immunocytochemistry. Expression of surface and 
intracellular antigens was studied immunocytochemi-
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cally using mouse monoclonal antibodies to P-glyco-
protein (Pgp), glutathione-S-transferase (GST), RE, PR, 
p53, Bcl-2, E-cadherin, Ki-67, cyclin D1, pRb, c-myc, 
p21 (“Dako Cytomation”, Denmark).
Flow cytometry.  For cell  cycle analysis 
of MCF-7 cells and its sublines, resistant to cisplatin 
(MCF-7/DDP) and doxorubicin (MCF-7/DOX), the cell 
suspension (106 cells per 200 µl of saline) was washed, 
2 ml of cold 70% ethanol was added, and suspension 
was fixed on ice for at least 30 min. Specimens were 
centrifuged for 5 min at 300 g with further super-
natant decantation. After resuspending the sample 
in 400 µl of saline, 50 µl of RNAse (25 mg/ml) and 
10 µl of propidium iodide (0.5 mg/ml) were added. 
Samples were analyzed on PAS “Partec” flow cyto-
meter (Germany) using red filter [17].
Electron microscopy. The cells were fixed in 1.6% 
glutharaldehyde solution in 0.1 M cacodylate buffer 
(pH 7.3) for 1 h followed by washing in 0.1 M cacody-
late buffer solution for 16–18 h. To achieve the isotonic 
state, sucrose (50 mg/ml) was added. Cell postfixa-
tion was done in 2% osmium tetraoxide with further 
dehydratation in alcohols and embedding in araldite 
as described elsewhere. The ultrathin sections pre-
pared on LKB-8800 ultratome and contrasted by uranil 
acetate and lead citrate were examined in JEM-100B 
electron microscope with 60 kV acceleration voltage 
with further specimen photography [18].
Statistical analysis. Statistical analysis was done 
using STATISTICA 6.0 software (StatSoft Inc., USA) 
with acquisition of mean values and standard deviation 
(SD). Student’s t-test was used to evaluate the signifi-
cance of the differences between groups. p > 0.05 was 
considered as the significant difference.
RESULTS AND DISCUSSION
Morphological features of sensitive and re-
sistant to cisplatin and doxorubicin MCF-7 cells. 
It is known, that the development of drug resistance 
phenotype is accompanied by the changes in different 
biological features of malignant cells, including mor-
phological ones. In contrast to spindle-shaped MCF-7 
and MCF-7/DOX cells, MCF-7/DDP cells were more 
spherical with high nucleus/cytoplasm ratio. In all three 
lines, the nuclei were rounded with 2–4 nucleoli. Cells 
resistant to doxorubicin and cisplatin were larger than 
initial MCF-7 cells and were characterized by stronger 
adhesion to the underlying surface. 
Electron microscopy demonstrated more com-
plicated ultrastructural organization and increased 
diffe rentiation grade upon formation of drug resis-
tance both to cisplatin and to doxorubicin (Fig. 1, a). 
The number of the microtubules increased and the 
fibers comprising the microfilaments of varying width 
were evident. An active Golgi apparatus consisting 
of 2–3 loci with many multivesicular bodies was also re-
vealed in the resistant cells (Fig. 1, b, c). The formation 
of a lot of multivesicular bodies and their positioning 
near the plasmatic membrane may be indicative of the 
increased efflux of the foreign substances through cell 
membrane, which decreases the amounts of cisplatin 
and doxorubicin in cytoplasm of resistant cells and 
their cytotoxic activity. In MCF-7/DDP cells, the system 
of actin filaments located in the cortical layer of cyto-
plasm was activated (see Fig. 1, b), while in MCF-7/DOX 
cells, the intermediate filaments were activated in the 
central area of cytoplasm (see Fig. 1, c). Therefore, the 
development of resistance to cisplatin and doxorubicin 
in MCF-7 cells was accompanied by the significant 
changes in ultrastructural organization suggestive 
of the increasing differentiation grade.
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Fig. 1. Electron microscopy of MCF-7 cells (a) and subclones 
with drug resistance to cisplatin MCF-7/DDP (b) and doxorubicin 
MCF-7/DOX (c)
Immunocy tochemical  characterist ics 
of MCF-7 cells, sensitive and resistant to cisplatin 
and doxorubicin. Mdr1 gene amplification followed 
by P-glycoprotein overexpression is one of the mecha-
nisms involved in the development of drug resistance. 
An alternative mechanism is connected with GST 
isoenzymes expression and increased metallothionein 
expression [19–21]. Glutathione-S-transferases are 
responsible for conjugating glutathione with different 
xenobiotics. The detoxification of anticancer drugs 
by metallothioneins is related to their linkage with 
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electrophilic antitumor drugs from cisplatin group, 
because free metallothioneins are nucleophilic com-
pounds [21]. In our experiments, P-gp expression was 
absent both in cisplatin-sensitive and resistant cells 
(Table 1, Fig. 2, a) suggesting mdr1-independent way 
of drug resistance. In contrast, in cytoplasm of most 
doxorubicin-resistant cells (MCF-7/DOX), P-gp was 
overexpressed (see Table 1; Fig. 2, c). Also we found 
out the significant differences in GST expression 
among the sublines studied. In cisplatin-resistant 
cells, the increase in GST content (Fig. 2, b) along with 
the decrease in the percentage of MT-positive cells 
(see Table 1) was evident.
According to current knowledge, receptor status 
of breast tumors is a prognostic factor that is con-
nected with their sensitivity to neoadjuvant therapy 
and radiotherapy. We have reported earlier that the 
drug resistance in MCF-7 human breast cancer cells 
developed upon cell culture in raising cisplatin and 
doxorubicin concentrations was accompanied by the 
changes in hormone receptor expression [22]. Par-
ticularly, estrogen and progesterone receptors were 
expressed in 20% and 40% respectively of the initial 
cells, while in MCF-7/DDP and MCF-7/DOX cells these 
receptors were absent (see Table 1). According to the 
clinical experience, in a third of breast cancer patients 
the worse prognosis is associated with the absence 
of steroid hormone receptors.
It is known that cytotoxic activity of many antitumor 
drugs is linked to their ability to induce apoptosis in tar-
get cells [23–25]. We have attempted to compare the 
content of several apoptosis-related proteins in MCF-7 
sublines with acquired drug resistance and in the ini-
tial MCF-7 cells. The acquisition of resistance to cis-
platin or doxorubicin was not associated with changes 
of p53 expression, which was detected at a low level in all 
cell lines studied (see Table 1). Antiapoptotic Bcl-2 pro-
tein was present in cytoplasm of almost all sensitive and 
doxorubicin-resistant cells (Fig. 2, d, f) while the long-
time culture of MCF-7 cells in the presence of cisplatin 
facilitated reduction of Bcl-2-positive cell percentage 
from 80 to 10% (see Table 1; Fig. 2, e). Therefore, the 
Table 1. Phenotypic features of breast cancer MCF-7 cells and sublines with induced resistance to cisplatin and doxorubicin
Cell line Cells, positive for studied proteins, %RE PR Pgp GST MT p53 Bcl2 Ki-67 E-cad С-myc p21 рRb Cyclin D
MCF-7 202, 3 402, 3 02 03 702, 3 602, 3 602, 3 402, 3 902, 3 15 103 602, 3 402, 3
MCF-7/DOX/16 01 01 701, 3 03 101 501 151 101 101 10 20 401 201
MCF7/DDP/4 01 01 02 701, 2 152 501 101 201 201 10 201 301 201
In Table 1 and 2: 1significantly (p < 0.05) different from MCF-7; 2significantly (p < 0.05) different from MCF-7/DOX/16; 3significantly (p < 0.05) different from MCF-7/DDP/4.
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Fig. 2. Imunocytochemical features of MCF-7 cells with cisplatin and doxorubicin drug resistance phenotype: а — loss of Pgp 
expression in sensitive MCF-7 cells; b — expression of GST in MCF-7/DDP cells; с — Pgp expression in MCF-7/DOX cells; d, е, f — 
Bcl-2 expression in MCF-7, MCF-7/DDP and MCF-7/DOX, respectively; g, h — Ki-67 expression in sensitive MCF-7 cells and 
MCF-7/DDP cells; i — р21 expression in MCF-7/DOX cells
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development of cisplatin resistance in breast cancer 
cells is associated with the lowered Bcl-2 expression. 
These data agree with both experimental and clinical find-
ings demonstrating that high Bcl-2 expression predicts 
chemosensitivity in breast and lung cancer.
We have also found decreased proliferative ac-
tivity of MCF-7 cells with resistance to cisplatin and 
doxorubicin (Fig. 2, g, h) with three-fold reduction 
of proliferative potential in MCF-7/DDP cells and two-
fold reduction in MCF-7/DOX cells (see Table 1). The 
decrease in the proliferative potential may be corre-
lated with differentiation of the resistant cells. In fact, 
both resistant variants (MCF-7/DOX and MCF-7/DDP) 
were characterized by strong expression of E-cadherin 
as compared to low expression of E-cadherin limited 
to the tight intercellular contact only in the initial MCF-7 
cells (see Table 1).
The decreased proliferative activity in cells acqui-
ring drug-resistant phenotype is believed to be as-
sociated with changes in the expression of some cell 
cycle-controlling proteins [26]. In our study, all three 
MCF-7 sublines expressed a low level of c-myc. The 
development of cisplatin and doxorubicin resistance 
in human breast cancer cells was accompanied by the 
reduction of cyclin D1, pRb expression and the overex-
pression of p21 (Fig. 2, i). These findings correspond 
with the available data of other authors [22, 26]. 
Therefore, the formation of drug resistance 
to cisplatin and doxorubicin in human breast cancer 
MCF-7 cells is characterized by changes in expression 
of proteins involved in control of apoptosis, cell cycle, 
proliferation, and adhesion.
Analysis of cell cycle in sensitive MCF-7 cells 
and cells with resistance to cisplatin and doxoru-
bicin. The abnormal regulation of cell cycle is known 
as one of the characteristic features of the malignant 
cells. We have shown that the patterns of cell cycle 
distribution in the initial MCF-7 cells are the same 
as in cisplatin and doxorubicin-resistant sublines 
(Table 2, Fig. 3). The mechanisms of cytotoxicity upon 
cell exposure to cisplatin and doxorubicin are diffe rent. 
It is believed that cisplatin is not a phase-specific drug 
because it causes disorders in DNA transcription and 
replication, which lead to cell cycle arrest and apoptosis. 
In contrast to cisplatin, doxorubicin is a phase-specific 
drug, affecting predominantly S and G2 phases of the 
cell cycle. It was of interest to compare cell cycle tra-
verse in the initial and resistant MCF-7 cells upon cell 
exposure to cisplatin and doxorubicin. We have shown 
that in the initial MCF-7 cells, incubation with cisplatin 
at a dose of IC10 for 24 h resulted in the significant de-
crease of S phase percentage (from 28.52% to 19.55%) 
with G2/M arrest (from 16.37% to 33.4%). Meanwhile, 
doxorubicin treatment resulted in the accumulation 
of MCF-7 cells in G0/G1 phase with the G0/G1 cell per-
centage increasing from 55.11% to 76.8%. In contrast, 
exposure to doxorubicin in MCF-7/DOX cells and ex-
posure to cisplatine in MCF-7/DDP cells had no effect 
on cell cycle traverse (Fig. 4).
Table 2. Cell cycle distribution of MCF-7 cells and sublines with induced 
resistance to cisplatin and doxorubicin 
Cell line Percentage of cells in a phase of the cell cycle G0/G1 S G2/M
MCF-7 55.11 28.52 16.37 
MCF-7/DOX/16 61.05 27.25 11.73 
MCF7/DDP/4 59.42 26.20 14.38 
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Fig. 3. Distribution of MCF-7, MCF-7/DDP, MCF-7/DOX cells 
between cell cycle phases
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Fig. 4. Changes in cell cycle as result of impact of studied 
antitumor drugs
To sum up, the long-time culture of human breast 
cancer MCF-7 cells in the presence of cisplatin or do-
xorubicin in vitro is accompanied by the pronounced 
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changes in molecular-biological properties of the cells 
with both shared and drug-specific molecular mecha-
nisms of the formation of the resistant phenotype. 
In both doxorubicin-resistant and cisplatin-resistant 
cells, the steroid hormone receptors have been lost. 
The development of cisplatin resistance involves the 
antiapoptotic mechanisms (decreased Bcl-2 expres-
sion) and intracellular glutathione detoxifying system 
while the development of doxorubicin resistance 
seems to follow MDR-dependent mechanism sugges-
ted by P-glycoprotein overexpression. In cells resistant 
to either cisplatin or doxorubicin, the adhesive proper-
ties are enhanced and the ultrastructural organization 
is characterized of more complicated patterns implying 
the increased differentiation grade. At the same time, 
in resistant cells cyclin D1, pRb, and Ki-67 expres-
sion decreased while р21 expression increased. The 
changed expression pattern suggests the decreased 
proliferative potential of the cells with drug resistant 
phenotype. Therefore, the resistant MCF-7 cells differ 
from the initial cell line by the expression of proteins 
associated with drug resistance as well as proteins 
involved in control of apoptosis, proliferation and cell 
adhesion. Our data may be advantageous for deve-
loping the novel schedules of anticancer treatment 
accounting for the molecular-biological characteristics 
of drug-resistant cells.
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